Lv5
960 积分 2023-08-30 加入
The story of amylin: from physiology to therapy
4天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
4天前
已完结
Calcitonin gene-related peptide (CGRP) and its role in hypertension
5天前
已完结
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
6天前
已完结
Amylin takes another shot at the obesity prize
6天前
已完结
RAMP1 and RAMP3 Differentially Control Amylin’s Effects on Food Intake, Glucose and Energy Balance in Male and Female Mice
7天前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
9天前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
9天前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
9天前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
9天前
已完结
皖公网安备34019202002308
